The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S28-S33 , October 2007

Daptomycin in the Treatment of Patients with Infective Endocarditis: Experience from a Registry

  • Donald P. Levine, MD

      Affiliations

    • Wayne State University, University Health Center, Detroit, Michigan, USA
    • ,
  • Kenneth C. Lamp, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Kenneth C. Lamp, PharmD, Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421.

References 

  1. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association—endorsed by the Infectious Diseases Society of America. [published corrections appear in Circulation. 2005;112:2373 and 2005;115:e408] Circulation. 2005;111:e394–e434
  2. Fowler VG, Miro JM, Hoen B, et al. ICE Investigators Staphylococcus aureus endocarditis: a consequence of medical progress. [published correction appears in JAMA. 2005;294:900] JAMA. 2005;293:3012–3021
  3. Baddour LM, Wilson WR. Principles and Practice of Infectious Diseases. In:  Mandell GL,  Bennett JE,  Dolin R editor. Infections of prosthetic valves and other cardiovascular devices. Philadelphia: Elsevier Churchill Livingstone; 2005;p. 1022–1044
  4. Chambers HF. The changing epidemiology of Staphylococcus aureus?. Emerg Infect Dis. 2001;7:178–182
  5. Smith TL, Pearson ML, Wilcox KR, et al. Glycopeptide-Intermediate Staphylococcus aureus Working Group Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999;340:493–501
  6. Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis. 2005;18:300–305
  7. Chang S, Sievert DM, Hageman JC, et al. Vancomycin-Resistant Staphylococcus aureus Investigative Team Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342–1347
  8. Mascini EM, Bonten MJ. Vancomycin-resistant enterococci: consequences for therapy and infection control. Clin Microbiol Infect. 2005;(suppl 4):43–56
  9. Torres-Viera C, Dembry LM. Approaches to vancomycin-resistant enterococci. Curr Opin Infect Dis. 2004;17:541–547
  10. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994–1000
  11. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs. 2004;13:1159–1169
  12. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681
  13. Fowler VG, Boucher HW, Corey R, et al. S. aureus Endocarditis and Bacteremia Study Group Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665
  14. Cubicin (daptomycin for injection). [prescribing information] Lexington, MA: Cubist Pharmaceuticals, Inc; 2006;
  15. Rolston KVI, Segreti JA, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007;120(suppl 10A):S4–S5
  16. Kennedy S, Chambers HF. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother. 1989;33:1522–1525
  17. Kaatz GW, Seo SM, Reddy VN, Bailey EM, Rybak MJ. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1990;34:2081–2085
  18. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:1714–1718
  19. Akins RL, Rybak MJ. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2001;45:454–459
  20. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: A retrospective case series of 31 patients. Pharmacotherapy. 2006;26:347–352

 Please see Author Disclosure section at the end of this article.

PII: S0002-9343(07)00662-6

doi: 10.1016/j.amjmed.2007.07.011

The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S28-S33 , October 2007

Article Tools